Advertisement

Research and Development of New Radiopharmaceuticals

  • Gerhard HollEmail author
Chapter
  • 1.7k Downloads

Abstract

The goal of research and development (R&D) for pharmaceutical companies is to find new products, to demonstrate that these are efficacious and safe, and to get them approved by the health authorities, thus making them available for broad use by the medical community. This comprises a long chain of activities, including identification of medical needs, extensive research work, preclinical preparation for administration of the new drug to humans, and a series of clinical studies. Although this chapter focuses on R&D of radiopharmaceuticals (RPs), general aspects of R&D of (nonradioactive) pharmaceutical products are also presented. Intravenous injection is always considered as the route of administration of RPs.

Keywords

Positron Emission Tomography Positron Emission Tomography Imaging Molecular Imaging Dementia With Lewy Body Positron Emission Tomography Tracer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Laufer EM, Winkens HM, Corsten MF, Reutelingsperger CP, Narula J, Hofstra L. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled Annexin A5. Q J Nucl Med Mol Imaging 53, 26–34 (2009).PubMedGoogle Scholar
  2. 2.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry, investigators, and reviewers, exploratory IND studies (2006). http://www.fda.gov/downloads/Drugs/Guidance/-ComplianceRegulatoryInformation/Guidances/ucm078933.pdf.
  3. 3.
    European Medicines Agency. ICH Topic M 3 (R2). Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. CPMP/ICH/286/95 (2009). http://www.ema.europa.eu/docs/en{_}GB/document{_}library/Scientific{_}guideline/2009/09/WC500002720.pdf.
  4. 4.
    Kirschner AS, Ice RD, Beierwaltes WH. Radiation dosimetry of 131I-19-iodocholesterol. J Nucl Med 14, 713–717 (1973); The authors’ reply. J Nucl Med 16, 248–249 (1975).Google Scholar
  5. 5.
    Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10, 201–227 (1982).CrossRefPubMedGoogle Scholar
  6. 6.
    O’Keefe GJ, Saunder TH, Gong SJ, Pathmaraj KU, Tochon-Danguy HJ, Villemagne VV, Krause S, Dyrks T, Dinkelborg L, Holl G, Rowe CC. Comparisons of animal human-translated and human 18F-BAY94–9172 amyloid radiation dosimetry. J Nucl Med 50 (Suppl 2), 1847 (2009).Google Scholar
  7. 7.
    Kolbert KS, Watson T, Matei C, Xu S, Koutcher JA, Sgouros G. Murine S factors for liver, spleen, and kidney. J Nucl Med 44, 784–791 (2003).Google Scholar
  8. 8.
    Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/CT: Important tools for preclinical investigation. J Nucl Med 49, 1651–1663 (2008).Google Scholar
  9. 9.
    Liang H, Yang Y, Yang K, Wu Y, Boone JM, Cherry SR. A microPET/CT system for in vivo small animal imaging. Phys Med Biol 52, 3881–3894 (2007).CrossRefPubMedGoogle Scholar
  10. 10.
    Duff K, Suleman F. Transgenic mouse models of Alzheimer’s disease: how useful have they been for therapeutic development? Brief Funct Genomics Proteomics 3, 47–59 (2004).CrossRefGoogle Scholar
  11. 11.
    European Medicines Agency. ICH Topic E 6 (R1). Guideline for good clinical practice. Step 5. Note for guidance on good clinical practice (CPMP/ICH/135/95) (2002). http://www.ema.europa.eu/docs/en{_}GB/document{_}library/Scientific{_}guideline/2009/09/WC500002874.pdf.
  12. 12.
    Zeng W. Communicating radiation exposure: a simple approach. J Nucl Med Technol 29,156–158 (2001).PubMedGoogle Scholar
  13. 13.
    Bundesamt für Strahlenschutz [German Federal Authority for Radiation Protection]. Home page http://www.bfs.de.
  14. 14.
    European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 2000. Eur J Nucl Med 29, BP13–BP19 (2002).Google Scholar
  15. 15.
    Chianelli M, Mather SJ, Grossmann A, Sobnack R, Fritzberg A, Britton KE, Signore A. 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune diseases: a feasibility study. Eur J Nucl Med Mol Imaging 35, 2286–2293 (2008).CrossRefPubMedGoogle Scholar
  16. 16.
    Love C, Tronco GG, Palestro CJ. Imaging of infection and inflammation with 99mTc-fanolesomab. Q J Nucl Med Mol Imaging 50, 113–120 (2006).PubMedGoogle Scholar
  17. 17.
    Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York. ISBN: 978-0-9320-0438-3 (1988).Google Scholar
  18. 18.
    International Commission on Radiological Protection. Annals of the ICRP. ICRP Publication 60. 1990 Recommendations of the ICRP. Elsevier, New York, ISBN: 978-0-08-041144-6 (1991).Google Scholar
  19. 19.
    International Commission on Radiological Protection. Annals of the ICRP. ICRP Publication 103. Recommendations of the ICRP. Elsevier, New York, ISBN: 978-0-7020-3048-2 (2008).Google Scholar
  20. 20.
    MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40, 37S–61S (1999).Google Scholar
  21. 21.
    He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I, Frey EC. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning – Monte Carlo simulation studies. IEEE Trans Med Imaging 27, 521–530 (2008).CrossRefPubMedGoogle Scholar
  22. 22.
    Sattler B, Barthel H, Seese A, Patt M, Schildan A, Starke A, Reininger C, Rohde B, Holl G, Gertz HJ, Hegerl U, Sabri O. Radiation risk caused by [F18]Bay 94-9172, a new PET tracer for detection of cerebral β-amyloid plaques. J Nucl Med 50 (Supplement 2), 1840 (2009).Google Scholar
  23. 23.
    International Commission on Radiological Protection. Annals of the ICRP. ICRP Publication 23. Reference man: anatomical, physiological and metabolic characteristics. Elsevier, New York, ISBN: 978-0-08-017024-4 (1975).Google Scholar
  24. 24.
    O’Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, Gong S, Dyrks T, Lindemann S, Holl G, Dinkelborg L, Villemagne V, Rowe CC. Radiation dosimetry ofβ-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 50, 309–315 (2009).CrossRefPubMedGoogle Scholar
  25. 25.
    Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46, 1023–1027 (2005).PubMedGoogle Scholar
  26. 26.
    Boroujerdi M. Pharmacokinetics: principles and applications. McGraw-Hill, New York, ISBN: 9780071351645 (2002).Google Scholar
  27. 27.
    Carson EC. Tracer kinetic modeling in PET. In: Valk PE, Bailey DL, Townsend DW, Maisey MN (editors). Positron emission tomography: basic science and clinical practice. Springer, London, 147–179. ISBN: 1 85233 798 2 (2003).Google Scholar
  28. 28.
    Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27, 1533–1539 (2007).CrossRefPubMedGoogle Scholar
  29. 29.
    Friston KF, Ashburner J, Kiebel SJ, Nichols TE, Penny WD (editors). Statistical parametric mapping: the analysis of functional brain images. Academic Press, London, ISBN: 9780123725608 (2007).Google Scholar
  30. 30.
    Jeong Y, Cho SS, Park JM, Kang SJ, Lee JS, Kang E, Na DL, Kim SE. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med 46, 233–239 (2005).PubMedGoogle Scholar
  31. 31.
    Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36, 1238–1248 (1995).PubMedGoogle Scholar
  32. 32.
    Mosconi L, Tsui WH, Herholz K, Pupi A, Drezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 49,390–398 (2008).CrossRefPubMedGoogle Scholar
  33. 33.
    Rowe CC, Ackermann U, Browne W, Mulligan R, Pike KL, O’Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehmann L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid β in Alzheimer’s disease with 18F-Bay94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7, 129–135 (2008).CrossRefPubMedGoogle Scholar
  34. 34.
    European Medicines Agency, Committee for proprietary medicinal products (CPMP). Points to consider on the evaluation of diagnostic agents, CPMP/EWP/1119/98 (2001). http://www.ema.europa.eu/docs/en{_}GB/document{_}library/Scientific{_}guideline/2009/09/WC500003655.pdf.

Copyright information

© Springer Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Bayer Schering Pharma, Clinical Development Molecular ImagingBerlinGermany

Personalised recommendations